Why the study?
Coronary microcirculation function predicts prognosis in ACS patients undergoing PCI, but the efficacy of ticagrelor on coronary microcirculation compared to clopidogrel remained unclear.
Does ticagrelor improve coronary microvascular function compared to clopidogrel in patients with ACS receiving PCI?
Does ticagrelor improve coronary microvascular function compared to clopidogrel in patients with ACS receiving PCI?
Ticagrelor significantly improves coronary microcirculatory resistance and myocardial perfusion compared to clopidogrel in ACS patients undergoing PCI.
Answers are grounded in this paper and cite their sources.
Supports ticagrelor preference in ACS-PCI for microvascular benefits; extends surrogate perfusion data amid uncertain hard outcomes.
BACKGROUND: The function of coronary microcirculation is an important factor in predicting the prognosis of patients with acute coronary syndrome (ACS) who receive percutaneous coronary intervention (PCI) therapy. Ticagrelor, a type of oral P2Y12 inhibitor, is widely prescribed to ACS patients and can improve prognosis compared to clopidogrel. However, the efficacy of ticagrelor on coronary microcirculation, compared to clopidogrel, remains unclear. The objective of this meta-analysis was to determine the efficacy of ticagrelor on coronary microcirculation. METHODS: The PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov databases were comprehensively searched to identify studies until November 2022. Data was pooled using the fixed effects model or random effects model based on the level of heterogeneity. Sensitivity analyses were performed to measure the effects of potential confounders. RESULTS: After screening, 16 trials with a total of 3676 participants were ultimately included in the analysis. The meta-analysis revealed that compared to clopidogrel, patients receiving ticagrelor exhibited a more significant reduction in the IMR (WMD: -6.23, 95% CI: -8.41 to -4.04), a reduction in the cTFC (WMD: -1.88; 95% CI: -3.32 to -0.45), and greater increases in CFR (WMD: 0.38; 95% CI: 0.18 to 0.57), MBG (RR 1.29, 95% CI 1.12 to 1.48), and TIMI (RR 1.03, 95% CI 1.00 to 1.06). CONCLUSION: Our findings suggest that, compared to clopidogrel, ticagrelor has a significant effect in reducing coronary microcirculatory resistance, enhancing coronary blood flow reserve, and improving myocardial perfusion.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: